2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-165019
    1-(3,4-Dichlorophenyl)-2-(dimethylamino)-1-propanone hydrochloride 2748344-06-9 98%
    1-(3,4-Dichlorophenyl)-2-(dimethylamino)-1-propanone hydrochloride is a drug derivative.
    1-(3,4-Dichlorophenyl)-2-(dimethylamino)-1-propanone hydrochloride
  • HY-165066
    EOS (d18:1/30:0/18:2) 97040-38-5 98%
    EOS (d18:1/30:0/18:2) is a kind ceramide in the outer epidermis.
    EOS (d18:1/30:0/18:2)
  • HY-165226
    β-Secretase-IN-5 5201-88-7
    β-Secretase-IN-5 is a Beta-secretase inhibitor. β-Secretase-IN-5 reduces the production of Aβ1-40 and Aβ1-42. β-Secretase-IN-5 is applicable to research related to Alzheimer's disease.
    β-Secretase-IN-5
  • HY-165281
    Chondrocurine 477-58-7
    Chondrocurine (Tubocurine) is an alkaloid found in the roots of Cissampelos pareira Linn. Chondrocurine is an acetylcholinesterase (AChE) inhibitor with an IC50 of 7.46 μM.
    Chondrocurine
  • HY-165323
    Pirisudanol 33605-94-6 98%
    Pirisudanol (pyrisuccideanol) is a psychostimulant. Pirisudanol can be used for the research of neurological disease, such as depression.
    Pirisudanol
  • HY-165341
    SCR1693 1442559-20-7 98%
    SCR1693 is a selective, reversible, orally active and noncompetitive inhibitor of AChE (IC50 = 0.68 μM) as well as a calcium channel blocker. SCR1693 reduces tau phosphorylation levels, and inhibits the generation and release of Aβ. SCR1693 restores insulin signaling and improves cognitive deficits. SCR1693 can be used for the study of Alzheimer's disease, especially which complicated with type 2 diabetes mellitus.
    SCR1693
  • HY-165387
    Nafenodone 92615-20-8 98%
    Nafenodone is an antidepressant agent. Nafenodone can reduce the rate and amplitude of contractions and lengthen sinus node recovery time. Nafenodone can inhibit the spontaneous mechanical activity in portal vein segmens with an IC50 of 1.4 μM in rat isolated vascular smooth muscle. Nafenodone relaxes the contractions induced by high K+ and noradrenaline.
    Nafenodone
  • HY-165391
    NA0359 134931-91-2
    NA0359 is a derivative of SF2370 (HY-N6732). NA0359 inhibits the actin-myosin-ATP interaction in native smooth muscle actomyosin and myosin light chain phosphorylation.
    NA0359
  • HY-165440
    Cyclobenzaprine 303-53-7 98%
    Cyclobenzaprine (MK130) is an orally active 5-HT2 receptor antagonist. Cyclobenzaprine acts centrally, providing skeletal muscle relaxation, alleviating muscle spasms, and reducing pain. Cyclobenzaprine also possesses antiparasitic activity. Cyclobenzaprine holds promise for research in the fields of acute, painful skeletal muscle disorders and infectious diseases.
    Cyclobenzaprine
  • HY-165444
    CP-615003 329016-45-7
    CP-615003 is a potent and subtype-selective partial agonist of GABAA receptor (GABAA receptor) (Ki = 1.1 μM). CP-615003 is mainly converted into the active metabolite CP-900725 through oxidative deamination in monkeys and humans, and the latter also has GABAA receptor affinity. CP-615003 is a substrate of P-glycoprotein (P-gp/MDR1), resulting in severe limitation of its penetration into the central nervous system (CNS). CP-615003 can be used for the study of CNS-related indications.
    CP-615003
  • HY-165469
    Methetoin 5696-06-0 98%
    Methetoin is an anticonvulsant.
    Methetoin
  • HY-165474
    TDPAM01 2231103-08-3
    TDPAM01 is a positive allosteric modulator of AMPA receptor GluA2. TDPAM01 can specifically bind to the ligand-binding domain (LBD) of GluA2 and shows an IC50 of 13.4 nM for the GluA2 flop subtype. TDPAM01 can stabilize the activated conformation of GluA2 receptors, delay the receptor deactivation or desensitization process, maintaining the rapid excitatory synaptic transmission in the central nervous system.
    TDPAM01
  • HY-165475
    TDPAM02 2231101-34-9
    TDPAM02 is a positive allosteric modulator of AMPA receptor GluA2. TDPAM02 can specifically bind to the ligand-binding domain (LBD) of GluA2 and shows an IC50 of 1.4 nM for the GluA2 flop subtype. TDPAM02 can stabilize the activated conformation of GluA2 receptors, delay the receptor deactivation or desensitization process, maintaining the rapid excitatory synaptic transmission in the central nervous system.
    TDPAM02
  • HY-165492
    Opc 14117 103233-65-4
    OPC-14117 is an orally active superoxide radical scavenger that can cross the blood-brain barrier. OPC-14117 inhibits the oxidative stress cascade reaction, significantly reducing the increase in tissue osmotic pressure and alleviating brain edema in the brain contusion model. OPC-14117 blocks the NF-κB-dependent apoptotic pathway in the striatum neuron apoptosis model induced by Quinolinic acid (HY-100807). OPC-14117 can reduce the necrotic volume, protect hippocampal CA3 neurons and restore cognitive function. OPC-14117 can be used to study secondary brain injury and improve neurological prognosis.
    Opc 14117
  • HY-165497
    Felbinac tris 935886-64-9 98%
    Felbinac tris (4-Biphenylacetic acid tris) is a potent analgesic agent. Felbinac tris metabolized into 4'-hydroxyfelbinac and is excreted via urine and feces. Felbinac tris has the potential for the research of post-operative pain.
    Felbinac tris
  • HY-165509
    DU172 321907-03-3
    DU172 is a ligand for the adenosine A1 receptor (Adenosine A1 Receptor), with an IC50 of 24.9 nM against A1AR and an IC50 of 0.42 μM against A2AAR.
    DU172
  • HY-165514
    Nafimidone 64212-22-2 98%
    Nafimidone is a stable and brain-penetrant antiepileptic compound Nafimidone shows effective anticonvulsant effects in kindled amygdaloid seizure model. However, The effective window of Nafimidone is narrow, and has obvious epileptogenic effects at high doses. Nafimidone can be used for the study of epilepsy.
    Nafimidone
  • HY-165527
    S18327 200398-40-9 98%
    S18327 is a multi-target antipsychotic agent. S18327 exerts its efficacy by acting on multiple neurotransmitter systems in the brain, and it has antagonistic effects on dopamine receptors (particularly the D2 receptor) and 5-hydroxytryptamine 2A receptors (5-HT2A receptor). S18327 can counteract excessive dopamine activity and hypo-function of glutamate. S18327 exhibits a multi-parameter pharmacological profile that is highly similar to that of Clozapine (HY-14539). S18327 can produce the same discriminative stimulus as Clozapine, improve cognitive filtering deficits associated with schizophrenia, and display anxiolytic properties. S18327 has relatively weak affinity for histaminergic receptors and muscarinic receptors, which avoids the side effects of Clozapine.
    S18327
  • HY-165539
    SMER10 221238-83-1
    SMER10 is a small-molecule enhancer that can induce autophagy. SMER10 can increase the number of EGFP-LC3 positive autophagosoms in COS-7 and HeLa cells, promoting the conversion of LC3-I to autophagosome-associated LC3-II. SMER10 can efficiently promote the degradation of autophagy substrates, including the mutant huntingtin protein (EGFP-HDQ74) associated with Huntington's disease and the A53T α-synuclein protein associated with Parkinson's disease. SMER10 exerts neuroprotective effect.
    SMER10
  • HY-165543
    SRI-29132 1482305-44-1 98%
    SRI-29132 is a potent leucine-rich repeat kinase 2 (LRRK2) inhibitor. SRI-29132 is promising for research of Parkinson’s disease.
    SRI-29132
Cat. No. Product Name / Synonyms Application Reactivity